TY - JOUR
T1 - CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
AU - Fukusumi, T.
AU - Ishii, H.
AU - Konno, M.
AU - Yasui, T.
AU - Nakahara, S.
AU - Takenaka, Y.
AU - Yamamoto, Y.
AU - Nishikawa, S.
AU - Kano, Y.
AU - Ogawa, H.
AU - Hasegawa, S.
AU - Hamabe, A.
AU - Haraguchi, N.
AU - Doki, Y.
AU - Mori, M.
AU - Inohara, H.
N1 - Funding Information:
We thank Miyuki Ozaki and Yuko Noguchi for their technical support. The current study was partly funded by a Core Research Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan; a Grant-in-Aid from the Third Term Comprehensive 10-year Strategy for Cancer Control of the Ministry of Health, Labour and Welfare, Japan; and grants from the Kobayashi Cancer Research Foundation, the Princess Takamatsu Cancer Research Fund, Japan; the SENSHIN Medical Research Foundation, Japan; and the National Institute of Biomedical Innovation, Japan.
PY - 2014/7/29
Y1 - 2014/7/29
N2 - Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.
AB - Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.
UR - http://www.scopus.com/inward/record.url?scp=84905277260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905277260&partnerID=8YFLogxK
U2 - 10.1038/bjc.2014.289
DO - 10.1038/bjc.2014.289
M3 - Article
C2 - 24874475
AN - SCOPUS:84905277260
VL - 111
SP - 506
EP - 514
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 3
ER -
